Quest Diagnostics (DGX) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is constructive — consensus is a manageable bar given Q1's strong beat and raised guidance, with the biggest swing factor being whether organic volume growth (ex-Corewell/Fresenius) can sustain its momentum and whether the ACA subsidy headwind finally shows up in the data.

Heading into Q2 2026, the bar for DGX looks achievable but not trivial. Consensus revenue of ~$2.97B implies roughly 7.6% YoY growth, consistent with management's raised full-year guide of $11.78B–$11.90B (6.8%–7.8% growth), and the company has beaten revenue estimates in each of the last eight quarters. Management's tone on the Q1 call was notably confident — they raised both revenue and EPS guidance, flagged that Corewell and Fresenius together contribute ~3.3% to revenue growth for the year, and guided to a cadence of just over 49% of revenue and EPS in H1 and just over 50% in H2, implying Q2 should be roughly in line with Q1 in absolute terms. Estimate revisions have been modestly positive since the Q1 print, with the Q2 consensus revenue estimate essentially unchanged at ~$2.97B and full-year EPS ticking up to ~$10.77 from ~$10.63 at the post-Q1 baseline, suggesting the Street has largely absorbed the guidance raise without getting ahead of itself. The stock has underperformed XLV since the Q1 print (+2.3% vs. +9.3% for XLV) — a relative lag that reflects some investor caution around PAMA reimbursement risk and Project Nova investment drag, rather than fundamental deterioration, and creates a setup where a clean beat could catalyze catch-up. The single biggest wildcard is the ACA subsidy expiration: management embedded a 30 bps revenue headwind in guidance but saw no measurable impact in Q1; if Q2 shows the first visible enrollment-to-utilization drop-off, it could weigh on volume guidance for H2 even if the quarter itself is fine.

Bar: Consensus revenue of $2.97B and adjusted EPS of $2.84 represent a moderate bar — achievable given the structural volume tailwinds from Corewell/Fresenius ramp and continued advanced diagnostics strength, but not a layup given the Project Nova expense ramp (>60% of $0.25 full-year dilution expected in H2, with Q2 ramping) and elevated fuel costs ($7M–$10M incremental headwind embedded in guidance).

Guidance/Tone: Management raised full-year 2026 revenue guidance to $11.78B–$11.90B and adjusted EPS to $10.63–$10.83 on the Q1 call — the second consecutive raise — and expressed confidence in the H2 cadence. No post-earnings guidance revisions have been issued. Tone is constructive: the Fresenius margin profile is expected to improve in H2 as that business ramps toward enterprise average margins, providing a natural tailwind to operating leverage.

Estimate Trajectory: Estimates have been stable-to-slightly-higher since the Q1 print. The Q2 revenue consensus of $2.97B is essentially flat vs. the post-Q1 baseline of $2.97B, while full-year EPS has drifted up modestly. The gap between consensus and guidance midpoint is narrow, suggesting limited cushion if volumes disappoint but also limited downside risk if the company simply executes to plan.

Stock Setup: DGX has lagged XLV materially since the Q1 print (+2.3% vs. +9.3%), trading at a modest discount to its historical average on a P/E basis. The relative underperformance is not fundamental — it reflects sector rotation into higher-beta healthcare names and PAMA overhang — and creates a setup where a clean Q2 beat with maintained or raised guidance could drive meaningful catch-up.

Wildcard: PAMA reimbursement reform. The data collection survey window runs May through end of July 2026 — closing right at earnings. Management is cautiously optimistic that broader hospital lab participation this cycle could result in upward rate pressure if the RESULTS Act does not pass, but any negative signal on submission rates or CBO scoring of the RESULTS Act could reignite rate-cut fears and pressure the stock regardless of the Q2 print.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a manageable but not low bar — revenue of $2.97B implies ~7.6% YoY growth, consistent with raised guidance, while adjusted EPS of $2.84 reflects the Project Nova ramp headwind. Organic requisition volume growth is the bigger swing factor: Q1 came in at 10.8% organic (7% from Corewell/Fresenius), and the Street is modeling ~7.8% for Q2, implying a deceleration in the two large partnerships' contribution as they lap their ramp — any upside in ex-partnership organic volume or revenue per requisition would be the key beat driver.

Table 1 — Q2 2026 Current Quarter Snapshot (All Key KPIs)

Source: Visible Alpha Consensus and Actuals Data. FY 2026 guidance midpoint based on Quest Diagnostics Q1 2026 earnings call (April 21, 2026): revenue $11.78B–$11.90B, adjusted EPS $10.63–$10.83. Q2 2026 consensus as of July 22, 2026.

Table 2 — Beat/Miss History (Last 8 Quarters) — Top 2 KPIs

Total Revenue

Diluted EPS — Operating (Adjusted)

Pattern: DGX has beaten consensus revenue estimates in all 8 of the last 8 quarters, with beat magnitude accelerating from ~0.3%–1.4% in 2024 to 1.9%–3.3% in 2025 and a standout +2.7% in Q1 2026 — a consistent beat culture that sets a high bar for the Street to model conservatively. Adjusted EPS beats have similarly been consistent, with the Q1 2026 beat of +4.9% the largest in the trailing 8-quarter window.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Management raised full-year 2026 guidance on the Q1 call (April 21, 2026) — the second consecutive raise — and has issued no post-earnings revisions since. Tone is constructive: the Fresenius margin ramp in H2, continued advanced diagnostics strength, and Project Nova expense cadence (>60% in H2) are all well-telegraphed, leaving little ambiguity in the setup.

Source: Quest Diagnostics Q1 2026 Earnings Call transcript (April 21, 2026); Visible Alpha Consensus Data.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been stable-to-modestly-higher since the Q1 2026 print — the Street has absorbed the guidance raise without getting ahead of itself. The narrow gap between consensus and guidance midpoint leaves limited cushion if volumes disappoint, but also signals the bar is not stretched. Full-year EPS estimates have drifted up ~$0.14 since the post-Q1 baseline, tracking the guidance raise closely.

Estimates have been remarkably stable since the Q1 print — the Street essentially repriced to the new guidance level immediately and has not moved since. The modest +1.3% drift up in FY EPS consensus reflects the guidance raise being absorbed, not incremental optimism. The slight tick-down in Q2 organic volume growth consensus (8.1% → 7.8%) reflects the Street modeling a natural deceleration from Q1's 10.8% as the Corewell/Fresenius ramp contribution normalizes.

Source: Visible Alpha Consensus and Actuals Data; Quest Diagnostics Q1 2026 Earnings Call (April 21, 2026).

5. Stock Performance

Key Takeaway: DGX has meaningfully underperformed XLV (+2.3% vs. +9.3%) and the S&P 500 (+6.2%) since the Q1 2026 earnings print — a gap driven by sector rotation into higher-beta healthcare names and PAMA overhang rather than fundamental deterioration, creating a setup where a clean Q2 beat could catalyze catch-up. The stock has recovered from its mid-May trough (~$187) to ~$210 as of July 22, 2026, but remains below the XLV-implied level.

DGX vs. XLV (Health Care Select Sector SPDR) vs. S&P 500 (SPY) — Indexed to 100 at Q1 2026 Earnings Date (April 21, 2026). Source: Stock Price Data.

Performance Summary (April 21 – July 22, 2026):

Key observations: DGX sold off from ~$205 to a trough of ~$187 by mid-May (roughly -9% from the earnings date), as the market digested the Project Nova investment ramp and PAMA uncertainty. The stock then recovered steadily through June and early July, reaching ~$216 on July 1 before pulling back to ~$210 ahead of earnings. The recovery was driven by improving sector sentiment and the $500M senior notes issuance (May 8, 2026) signaling management confidence in the balance sheet. Post-market on July 22, DGX is indicated at ~$215, suggesting the market is anticipating a positive print.

Source: Stock Price Data (Yahoo Finance).

6. Peer Commentaries — Read-Through for Q2 2026

Key Takeaway: Peer commentary since the Q1 2026 earnings cycle is broadly positive for DGX's Q2 setup — Labcorp confirmed continued diagnostic volume momentum and specialty testing strength, Natera's record oncology volumes validate advanced diagnostics demand, and Guardant Health's 47% oncology volume growth and Shield screening momentum confirm the structural shift toward liquid biopsy and preventive testing that benefits Quest's advanced diagnostics franchise. Danaher's Q2 2026 results (reported July 21) show clinical diagnostics growing mid-single digits globally, consistent with a healthy underlying lab testing environment.

Note: Only commentary from peers about Q2 2026 (the current reporting quarter) or forward-looking commentary made after their Q1 2026 earnings is included. Prior-quarter results commentary is excluded.

Labcorp (LH) — Q1 2026 Earnings Call (April 30, 2026) — Q2 2026 Outlook

Read-Through Relevance: Labcorp is DGX's closest direct peer in clinical diagnostics. LH's Q2 2026 commentary is the most direct read-through for volume trends, pricing dynamics, ACA impact, and PAMA positioning.

• Volume momentum confirmed heading into Q2: Labcorp management said they are "encouraged to head into the second quarter of this year" and feel "confident in the guidance" with "momentum to get there." Diagnostic Laboratories delivered 5% revenue growth in Q1 with 2.9% organic growth, and organic volume growth of 1.1% (constrained by ~$15M weather impact; ex-weather, organic volume growth would have been ~2%).
• Read-through for DGX: LH's organic volume growth of ~2% (ex-weather) is well below DGX's 3.8% ex-Corewell/Fresenius, confirming Quest's structural outperformance in organic volume. The weather impact commentary is consistent with DGX's Q1 disclosure (~$9M revenue impact), and both companies noted strong patient recapture rates.
• Specialty testing driving price/mix: LH's price/mix increased 2.6% in Diagnostics, "primarily due to an increase in test per assessment" — directly mirroring DGX's tests-per-requisition step-up narrative. Neurology saw "double-digit growth, driven by our market-leading portfolio in Alzheimer's testing" and oncology also achieved "double-digit growth, supported by the launch of several liquid biopsy tests."
• Read-through for DGX: Validates DGX's advanced diagnostics thesis — Alzheimer's testing (AD-Detect) and oncology (Haystack MRD) are structural growth drivers, not one-quarter phenomena. The tests-per-requisition dynamic is industry-wide.
• ACA impact immaterial in Q1, 30 bps assumption retained: LH said the ACA impact in Q1 was "immaterial" and year-to-date enrollment is "slightly better than expectations," but they continue to model 30 bps of volume impact for the full year. They are monitoring whether enrolled participants are paying premiums and converting to utilization.
• Read-through for DGX: Identical posture to DGX — both companies retained the 30 bps headwind assumption despite seeing no Q1 impact. Q2 is the first real test for both. If LH's Q2 results (reporting July 30) show no ACA impact, it would be a positive read-through for DGX.
• PAMA: RESULTS Act advocacy, data submission confirmed: LH confirmed it will submit PAMA data and is actively advocating for the RESULTS Act, noting "there is an understanding across the Senate, across Congress that a long-term permanent fix needs to be enacted." LH noted that if PAMA is implemented in January, "over time, it actually will increase the pipeline of deals because these local regional laboratories are under a lot of stress already."
• Read-through for DGX: Both companies are aligned on PAMA strategy. LH's comment that PAMA could accelerate M&A pipeline is consistent with DGX's Co-Lab strategy — financially stressed regional labs become acquisition or partnership targets.
• Hospital outsourcing pipeline "remains very strong": LH announced a nationwide collaboration with Children's Hospital of Philadelphia, acquired Crouse Health's Laboratory Alliance of Central New York, and is on track to close Parkview Health outreach lab acquisition. Management noted health systems are "struggling right now, and they are looking for ways to partner."
• Read-through for DGX: Validates DGX's Co-Lab strategy. The hospital outsourcing pipeline is robust industry-wide, supporting DGX's Corewell Health partnership and future Co-Lab wins.
• Fuel costs: minimal impact for LH vs. $7M–$10M for DGX: LH said fuel costs represent "approximately $5 million to $10 million" AOI impact for the year and is "manageable." DGX guided to a similar $7M–$10M incremental headwind. Both companies have embedded this in guidance.

Natera (NTRA) — Q1 2026 Earnings Call (May 7, 2026) — Q2 2026 Outlook & Advanced Diagnostics

Read-Through Relevance: Natera is the leading MRD/oncology liquid biopsy company. Its commentary on oncology testing demand, Signatera volume growth, and physician adoption is a read-through for DGX's Haystack MRD franchise and advanced diagnostics growth.

• Record oncology volumes confirm structural demand: Natera processed 249,000 clinical oncology units in Q1 2026, representing 55% growth YoY and a record increase of ~24,000 units over Q4. The company is now on a run rate of over 1 million MRD tests annually. Management noted that "approximately 45%–50% of oncologists had tried Signatera in the quarter," indicating significant room for further penetration.
• Read-through for DGX: The explosive growth in MRD testing validates DGX's Haystack MRD investment. As the lab processing partner for many oncology tests, Quest benefits from volume growth across the MRD ecosystem. The 50% oncologist penetration figure also suggests the market is still in early innings.
• Q2 2026 volume outlook: seasonal deceleration in women's health, continued oncology growth: Natera guided that Q2 is "the slowest" quarter for women's health due to seasonality, with recovery in H2. Signatera volumes are expected to continue growing "along the lines of the trailing 12-month average."
• Read-through for DGX: The seasonal pattern in women's health (Q1 strongest, Q2 slowest) is relevant for DGX's consumer channel, which includes prenatal and women's health testing. DGX's consumer channel grew in the high-20s in Q1; a seasonal moderation in Q2 would be expected and is likely already in consensus.
• Signatera ASP rising: $1,250 in Q1, targeting $1,275 exit 2026: Natera's Signatera ASP reached ~$1,250 in Q1, up ~$25 from Q4, with the new revenue guide implying an exit ASP of ~$1,275 for 2026. The long-term target remains $2,000 per test.
• Read-through for DGX: Rising ASPs in MRD testing are a positive for DGX's revenue per requisition trajectory, as advanced diagnostics tests carry higher reimbursement than routine tests. The structural ASP improvement in the MRD category supports DGX's tests-per-requisition and revenue-per-requisition growth narrative.
• Surgical de-escalation data driving new use cases: Natera highlighted data showing MRD-negative patients avoiding surgery in bladder, rectal, and breast cancer with excellent outcomes. Physicians are "very enthusiastic" about this new data. The concept of "Treatment on MRD" (TOMR) is gaining traction across multiple pharma-sponsored trials.
• Read-through for DGX: New clinical use cases for MRD testing expand the total addressable market for advanced diagnostics, benefiting DGX's Haystack franchise and its broader oncology testing portfolio.

Guardant Health (GH) — Q1 2026 Earnings Call (May 7, 2026) & Jefferies Conference (June 3, 2026)

Read-Through Relevance: Guardant is the leading liquid biopsy company for oncology and colorectal cancer screening. Its commentary on oncology volume growth, Shield screening momentum, and the Quest collaboration is a direct read-through for DGX's advanced diagnostics and consumer channel.

• 47% oncology volume growth — "fastest in nearly 3 years": Guardant reported 47% oncology volume growth in Q1 2026, the highest YoY percentage growth in nearly 3 years, with Guardant360 Liquid up 30% and Reveal (MRD) up over 100%. Management noted growth is "broad-based" with "a lot of share gains" and "greater depth and breadth" among physicians.
• Read-through for DGX: The explosive growth in liquid biopsy and MRD testing is a structural tailwind for DGX's advanced diagnostics franchise. Quest processes tests for multiple liquid biopsy companies and benefits from the overall market expansion.
• Quest collaboration driving Shield screening momentum: Guardant's Shield colorectal cancer screening test generated $42M in revenue from ~44,000 tests in Q1 2026 (vs. $6M and 9,000 tests in Q1 2025). The Quest collaboration "launched nationwide in late Q1" and is showing "positive early signals," opening doors in health systems and physician practices. Management cited the Quest collaboration as a key driver of March momentum.
• Read-through for DGX: The Quest-Guardant Shield collaboration is a direct revenue contributor for DGX — Quest processes Shield tests and provides the blood draw infrastructure. Guardant's guidance for 230,000–245,000 Shield tests in FY2026 implies continued volume growth through Q2–Q4, which flows through to DGX's consumer channel and requisition volumes.
• ACS guidelines inclusion — positive volume catalyst for Q2 and beyond: At the Jefferies conference (June 3), Guardant management said ACS guidelines inclusion was expected "any day" and would have a "positive impact on volume for the remainder of 2026." The guidelines were subsequently published, and Guardant noted that roughly a dozen states mandate commercial payer coverage once a test is in ACS guidelines.
• Read-through for DGX: ACS guideline inclusion for Shield is a positive for DGX's consumer channel and its role as the processing lab for Shield tests. Increased Shield volume in Q2–Q4 2026 would benefit DGX's requisition volumes and consumer channel revenue.
• DTC and influencer campaigns driving brand awareness: Guardant launched DTC and influencer campaigns in Q1 (featuring Patrick Dempsey), generating "over 1 billion impressions." Management noted that "incredibly strong brand awareness of Shield" is now established, with doctors already having heard of Shield before reps arrive.
• Read-through for DGX: Increased consumer awareness of blood-based cancer screening tests benefits DGX's consumer channel broadly — patients who learn about Shield through DTC campaigns are directed to Quest PSCs for blood draws, driving incremental consumer channel volume.
• Guardant360 FDA approval received — ASP upside catalyst: At the Jefferies conference, Guardant confirmed FDA approval for Guardant360 Liquid, setting the cash pay price at $8,455 (up from $5,000). The company expects DLT status in H1 2027, which would increase Medicare fee-for-service rates.
• Read-through for DGX: Higher ASPs for FDA-approved liquid biopsy tests benefit DGX's revenue per requisition as it processes these tests. The FDA approval also validates the clinical utility of liquid biopsy, supporting physician adoption and volume growth.

Danaher (DHR) — Q2 2026 Earnings Call (July 21, 2026) — Diagnostic Market Environment

Read-Through Relevance: Danaher's diagnostics segment (Beckman Coulter, Cepheid, Leica Biosystems) is a supplier to and indicator of the broader clinical diagnostics market. DHR's Q2 2026 results (reported one day before DGX's earnings) provide the most timely read on the diagnostic testing environment.

• Clinical diagnostics growing mid-single digits globally in Q2 2026: Danaher's diagnostics segment core revenue increased 2% in Q2 (5% ex-respiratory). Clinical diagnostics businesses grew "mid-single digits" globally, with "high single-digit growth outside of China." Beckman Coulter Diagnostics grew "mid-single digits globally" with "solid immunoassay revenue and install base growth."
• Read-through for DGX: Mid-single-digit clinical diagnostics growth at Beckman (a key instrument supplier to Quest) is consistent with a healthy underlying testing environment. The high single-digit growth ex-China suggests the U.S. and European diagnostic markets remain robust heading into DGX's Q2 print.
• Cepheid non-respiratory revenue up low double digits: Cepheid's core non-respiratory revenue increased "low double digits" in Q2, led by hospital-acquired infection and sexual health assays, with "several notable key account wins with large hospital networks."
• Read-through for DGX: Strong infectious disease and specialty testing demand at Cepheid is consistent with DGX's advanced diagnostics growth narrative. Hospital network wins at Cepheid also validate the hospital channel strength that DGX has been reporting.
• Alzheimer's biomarker tests: Beckman introduced P-Tau217 assays: Beckman Coulter introduced the Access Brain Derived P-Tau217 research use only assay and received CE mark approval for the Access P-Tau217 assay — blood-based Alzheimer's biomarker tests for use on the Dxi 9000. DHR noted these "further strengthen Beckman's positioning as a leader in the important and growing area of neurodegenerative diagnostics."
• Read-through for DGX: The expansion of Alzheimer's blood-based testing infrastructure (instruments, assays) by Beckman validates the structural growth in this category. DGX's AD-Detect testing more than doubled YoY in Q1 2026; Beckman's new assays could expand the physician base ordering Alzheimer's blood tests, benefiting DGX's volume.
• Underlying diagnostic trends expected to continue in H2 2026: DHR guided to Q3 core revenue growth of ~2%–3% (5% ex-respiratory) and expects to "exit Q4 at the mid-single digit core revenue growth rate." Management noted "encouraging signs of stabilization and improvement across end markets" with "clinical and applied markets consistently remaining sources of strength."
• Read-through for DGX: Danaher's constructive H2 2026 outlook for clinical diagnostics is a positive leading indicator for DGX's Q2 and H2 volume trends. The "clinical and applied markets consistently remaining sources of strength" comment is directly applicable to Quest's core business.
• Academic/government market stabilization — limited DGX impact: DHR noted academic and government markets have "largely stabilized" but represent less than 5% of Danaher's revenues. This segment is not material for DGX, which derives the vast majority of revenue from clinical testing.

Peer Read-Through Summary Table

Overall peer read-through is uniformly positive for DGX's Q2 2026 setup: diagnostic volume trends are healthy, advanced diagnostics demand is structural and accelerating, the ACA headwind has not materialized, and the Quest-Guardant Shield collaboration is generating incremental consumer channel volume. The only potential negative read-through is Natera's expected Q2 seasonal slowdown in women's health, which could modestly weigh on DGX's consumer channel, but this is already embedded in consensus.

7. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the $500M senior notes issuance (May 8, 2026), which signals management confidence in the balance sheet and provides capital for M&A and Project Nova investment. The PAMA data collection window closing at end of July is the key regulatory overhang heading into the print.

• May 8, 2026 — Quest issues $500M Senior Notes due 2036 (8-K): Quest priced and closed a $500M senior notes offering due 2036. This is the most significant capital markets action since Q1 earnings and signals management confidence in the long-term business trajectory. Proceeds are expected to be used for general corporate purposes, including potential M&A and Project Nova investment. Implication: Positive for balance sheet flexibility; management's willingness to issue long-dated debt at current rates signals confidence in the earnings power trajectory. Watch for any M&A announcement on the Q2 call.
• July 23, 2026 — Q2 2026 Earnings Release (scheduled): Quest Diagnostics is scheduled to release Q2 2026 financial results on July 23, 2026, as announced June 17, 2026. Implication: Tomorrow's print. All eyes on organic volume growth ex-Corewell/Fresenius, revenue per requisition trajectory, and any update to FY2026 guidance.
• May–July 2026 — PAMA data collection survey window open: The PAMA data collection survey window runs from May 1 through end of July 2026. CMS has stated potential fines of up to $10,000/day for non-submission. Over 2,600 hospital labs are required to submit. Quest has confirmed it will submit. The RESULTS Act (80+ cosponsors) is the legislative alternative that would keep rates unchanged for 2027. Implication: The data collection window closes right at earnings. Management will likely provide an update on submission rates and RESULTS Act progress. Broader hospital lab participation this cycle could result in upward rate pressure — a potential positive surprise.
• April 30, 2026 — Labcorp raises FY2026 guidance after Q1 beat: Labcorp raised its FY2026 enterprise revenue guidance midpoint by ~$30M and EPS midpoint by $0.13 after a strong Q1. Diagnostic Laboratories revenue grew 5% with 2.9% organic growth. Implication: Positive read-through for DGX — the industry leader in clinical diagnostics is also raising guidance, validating the structural volume tailwinds.
• May 7, 2026 — Guardant Health raises FY2026 guidance; Quest collaboration live: Guardant raised FY2026 revenue guidance to $1.30B–$1.32B (32%–34% growth) after Q1 revenue of $302M (+48% YoY). The Quest collaboration launched nationwide in late Q1, driving Shield screening volume. Implication: Direct positive for DGX's consumer channel — Shield volume growth flows through Quest's blood draw network and processing labs.
• June 3, 2026 — Guardant confirms ACS guideline inclusion imminent (Jefferies Conference): Guardant management said ACS guidelines for Shield were expected "any day" and would have a "positive impact on volume for the remainder of 2026." ACS guidelines were subsequently published. Implication: ACS guideline inclusion expands Shield's addressable market to commercial payers in ~12 states, driving incremental volume through Quest's network in Q2–Q4 2026.
• July 21, 2026 — Danaher Q2 2026 results confirm healthy diagnostic market: Danaher reported Q2 2026 diagnostics segment core revenue +2% (+5% ex-respiratory), with clinical diagnostics growing mid-single digits globally. Beckman Coulter Diagnostics grew mid-single digits with solid immunoassay revenue. Cepheid non-respiratory revenue up low double digits. Implication: The most timely read on the diagnostic testing environment — healthy underlying demand confirmed for Q2 2026, one day before DGX's print.
• June 17, 2026 — Quest announces Q2 2026 earnings date of July 23, 2026: Standard earnings date announcement. No guidance update or pre-announcement included. Implication: Absence of a pre-announcement (positive or negative) is itself informative — no material deviation from guidance was required.

8. Insider Transaction Activity

Key Takeaway: The only notable open-market activity is CEO Jim Davis's 10,000-share sale on June 1, 2026 under a 10b5-1 plan — a pre-scheduled, plan-driven transaction that is not a discretionary signal. SVP Karthik Kuppusamy also executed a 10b5-1 plan sale in June. The bulk of activity since Q1 earnings consists of routine director equity award grants (code A) and dividend equivalent reinvestments (code L), which carry no informational content. No open-market buys or unusual discretionary sales are present.

Assessment: Nothing stands out. The CEO and SVP sales are both under pre-established 10b5-1 plans — obligation-driven, not discretionary. The absence of any open-market buys is neutral (not unusual for a company trading near all-time highs). The cluster of director grants in May reflects the annual equity compensation cycle. No insider activity since Q1 earnings provides a meaningful signal for the Q2 print.

Source: Insider Transaction Data (SEC Form 4 filings).